Bleeding risk ends aspirin-clopidogrel trial

10/10/2011 | TheHeart.org (Montreal) (free registration)

The National Institute of Neurological Disorders and Stroke has halted the study of an aspirin-clopidogrel combination in the Secondary Prevention of Small Subcortical Strokes trial. Mortality rates and bleeding risk were higher for that combination, and an analysis showed little chance of benefit.

View Full Article in:

TheHeart.org (Montreal) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC